Boehringer Ingelheim is planning to increase the production capacity for its Respimat® inhaler to 44 million units per year and will invest more than €100 million to enlarge its Dortmund site. Some 100 new jobs are expected to be created at the site. The Dortmund’s site was created in 2004 upon the acquisition of the microtechnology company STEAG microParts GmbH, which was integrated into the group. The device is then filled with the relevant active pharmaceutical ingredients at the company’s headquarters in Ingelheim to be distributed worldwide. Boehringer Ingelheim is also investing additional €72 million at the Ingelheim’s site for the expansion of the Respimat production.